Group 1 - The company reported a revenue of RMB 38 million for the six months ending June 30, 2025, a significant increase of RMB 37.9 million compared to RMB 100,000 for the same period ending June 30, 2024, primarily due to recent payments received from the licensing and collaboration agreement with Axion Bio, Inc. [1] - Research and development expenses rose by 41.0% to RMB 168 million for the six months ending June 30, 2025, up from RMB 119.1 million for the same period in 2024, driven by increased preclinical and CMC expenses, clinical trial costs, and expanded clinical team salaries [1][1][1] - The increase in R&D spending included an additional RMB 43.4 million for preclinical and CMC expenses, RMB 8.3 million for clinical trial costs, and RMB 4.9 million for salaries and related benefits, partially offset by a decrease of RMB 6.7 million in share-based payments due to a reduction in the number of restricted shares vested [1][1][1]
宜明昂科-B(01541.HK)：中期实现收入3800万元